HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Loss of disialyl Lewis(a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-7 (Siglec-7) associated with increased sialyl Lewis(a) expression on human colon cancers.

Abstract
Expression of sialyl Lewis(a) is known to be increased in cancers of the digestive organs. The determinant serves as a ligand for E-selectin and mediates hematogenous metastasis of cancers. In contrast, disialyl Lewis(a), which has an extra sialic acid attached at the C6-position of penultimate GlcNAc in sialyl Lewis(a), is expressed preferentially on nonmalignant colonic epithelial cells, and its expression decreases significantly on malignant transformation. Introduction of the gene for an alpha2-->6 sialyl-transferase responsible for disialyl Lewis(a) synthesis to colon cancer cells resulted in a marked increase in disialyl Lewis(a) expression and corresponding decrease in sialyl Lewis(a) expression. This was accompanied by the complete loss of E-selectin binding activity of the cells. In contrast, the transfected cells acquired significant binding activity to sialic acid-binding immunoglobulin-like lectin-7 (Siglec-7)/p75/adhesion inhibitory receptor molecule-1, an inhibitory receptor expressed on lymphoid cells. These results indicate that the transition of carbohydrate determinants from disialyl Lewis(a)-dominant status to sialyl Lewis(a)-dominant status on malignant transformation has a dual functional consequence: the loss of normal cell-cell recognition between mucosal epithelial cells and lymphoid cells on one hand and the gain of E-selectin binding activity on the other. The transcription of a gene encoding the alpha2-->6 sialyltransferase was markedly down-regulated in cancer cells compared with nonmalignant epithelial cells, which is in line with the decreased expression of disialyl Lewis(a) and increased expression of sialyl Lewis(a) in cancers. Treatment of cancer cells with butyrate or 5-azacytidine induced strongly disialyl Lewis(a) expression, suggesting that histone deacetylation and/or DNA methylation may be involved in the silencing of the gene in cancers.
AuthorsKeiko Miyazaki, Katsuyuki Ohmori, Mineko Izawa, Tetsufumi Koike, Kensuke Kumamoto, Koichi Furukawa, Takayuki Ando, Makoto Kiso, Toshiyuki Yamaji, Yasuhiro Hashimoto, Akemi Suzuki, Aruto Yoshida, Makoto Takeuchi, Reiji Kannagi
JournalCancer research (Cancer Res) Vol. 64 Issue 13 Pg. 4498-505 (Jul 01 2004) ISSN: 0008-5472 [Print] United States
PMID15231659 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Differentiation, Myelomonocytic
  • Antigens, Tumor-Associated, Carbohydrate
  • CA-19-9 Antigen
  • DNA, Complementary
  • Lectins
  • RNA, Messenger
  • SIGLEC7 protein, human
  • disialyl Lewis a antigen
  • GalNAc sialyltransferase VI
  • Sialyltransferases
Topics
  • Antigens, Differentiation, Myelomonocytic (metabolism)
  • Antigens, Tumor-Associated, Carbohydrate (metabolism)
  • CA-19-9 Antigen
  • Carbohydrate Sequence
  • Cell Adhesion (physiology)
  • Colonic Neoplasms (genetics, immunology, metabolism)
  • DNA, Complementary (genetics)
  • Humans
  • Lectins (metabolism)
  • Lymphocytes (cytology)
  • Molecular Sequence Data
  • RNA, Messenger (biosynthesis, genetics)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sialyltransferases (biosynthesis, genetics)
  • Transfection
  • Tumor Cells, Cultured
  • U937 Cells

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: